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Summary
Objective: To investigate the relevance of serum topiramate (TPM) levels (SL)
monitoring in the clinical management of epileptic patients.
Methods: Twenty-seven patients with different epileptic syndromes on TPM therapy
were studied.
TPM was used as add-on in 26 patients, only in one as monotherapy de novo; one
case changed from TPM as add-on to TPM monotherapy. The mean follow-up time was
11 months. TPM SL were measured by fluorescence polarization immunoassay.
Results: We analyzed the TPM SL in 43 samples from 27 patients. Mean TPM dose was
3.9 mg/kg, mean TPM SL 13.43 mmol/l. The mean level to dose ratio (LDR) was
3.63 mmol/l/mg/kg.
Four patients became seizure-free, all with TPM dosages lower than the mean.
Eleven patients had at least 50% seizure reduction.
The comedication with enzyme-inducing AED significantly reduced TPM SL and
LDR. On the other hand, the influence of valproic acid (VPA) on TPM LDR was not
univocal. Indeed, patients younger than 15 years showed SL values lower than the
adults did, although not significant.
Conclusion: We could not detect a direct relationship between high TPM SL and
efficacy neither between high TPM SL and tolerability. However, the data we collected
seem to favour the hypothesis that high TPM dosage and SL might be associated to a
greater probability to reduce seizure severity.
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The pharmacokinetic profile of TPM is characterized
by a rapid and nearly complete absorption, unaf-
fected by food, linear kinetics, no autoinduction, no
active metabolites, low binding to plasma proteins,
which limits its interaction potential, predominant
renal elimination, long elimination half-life allowing
b.i.d. dosing with or without hepatic-enzyme indu-
cers.1,2
Pharmacokinetic interactions with other AEDs are
limited to increased TPM plasma clearance in pre-
sence of hepatic enzyme inducers [e.g. phenytoin
(PHT), carbamazepine (CBZ)]. TPMmay also increase
PHT serum levels (SL) in some patients.2—6 It’s well
known that during valproate (VPA) cotherapy, a slight
but statistically significantdecrease inbothTPM(15—
17%) and VPA (11%) SL were observed.2,5,30 On the
contrary, in a more recent study, no significant influ-
ence of VPA on TPM SL was found.6
Clinically relevant pharmacokinetic interactions
between TPM and other new AEDs have not beenTable 1 Clinical data of 27 patients treated with topirama
Patients
number
Sex Age Syndrome Aetiology Sei
1 F 26 F sympt A-I post F-T
2 M 15 F sympt Infectious TC-
3 F 37 F sympt Malformative F
4 F 40 F sympt Malformative F-T
5 M 32 F sympt Infectious F
6 F 31 F sympt A-I post F-F
7 F 46 F sympt Infectious F-T
8 M 22 G sympt Infectious T-A
9 M 22 F sympt Unknown F-F
10 M 23 F sympt A-I peri F
11 M 15 F sympt A-I peri F-F
12 F 29 G sympt Malformative M-A
13 F 2 G sympt Unknown SP
14 M 24 F sympt Coeliac dis. F-T
15 F 32 F sympt Unknown F
16 M 16 F sympt Malformative FSG
17 M 7 F sympt Infectious F
18 M 13 F sympt A-I post F
19 M 8 F sympt A-I peri F
20 M 31 Indet Unknown TC
21 F 15 F sympt A-I post F-F
22 M 26 Progr.myocl Genetic M-T
23 F 27 Progr.myocl Genetic M-T
24 M 34 F crypt Unknown FSG
25 M 12 F crypt Unknown F
26 M 1.3 F sympt Hypot.hamart F-F
27 F 9 F sympt Post-traumatic F
A-I = anoxic—ischaemic damage (pre/peri/post-natal); F = focal;
TC = tonic—clonic; T = tonic; AT = atonic; AA = atypical absence; M =
genie; Progr.myocl. = progressive myoclonic; Indet = indeterminat
GBP = gabapentin; LTG = lamotrigine; PB = phenobarbital; PHT = phreported,2 in particular no significant impact with
lamotrigine is known.38 The most relevant interac-
tions between TPM and not-antiepileptic drugs in
literature are relative to oral contraceptive (with
TPM dosages higher than 200 mg/die), digoxine,
lithium, amitriptyline, propranolol, but effects
are relatively modest.28,29,37,38 Higher mg per kg
dosages may be necessary in children and infants
because of increased TPM clearance rates.2,6—10
The relationship between TPM dose and efficacy
has been well established from several clinical
trials.11—15 On the other hand, the relationship
between TPM SL and clinical course has not been
so widely investigated. Considerable overlap exists
in TPM SL between responders and not responders16
as between patients experiencing adverse effects
and those who do not.
So, no recommendations for a therapeutic range
of TPM SL can be derived from the studies till now
reported except a recent randomized, concentra-
tion-controlled trial of TPM in refractory focal epi-
lepsy. This trial indicates low-medium levelste
zures Frequency Concomitant AEDs Follow-up
(months)
C 5/day CBZ-CLB 24
T 20/month CBZ-CLB 17
5/month CBZ-CZP 17
C 90/month CBZ-GBP-CLB 15
90/month CBZ-VGB 14
SG 6/month CBZ-PB 16
C 28/month CBZ-PB 24
T 70/month CBZ-VPA 36
SG 105/month CBZ-VPA-CLB 14
3 5/month CBZ-VPA 13
SG 12/month CBZ 8
A-TC 6/day PB-LTG 20
55/day VPA 6
C-AA-AT 5/day VPA-LTG 30
5/month VPA-PHT-CLB 3
8/month VPA 16
60/month VPA 6
15/month VPA 3
<1/month PB 3
3/month PB-VPA 2
SG 3 /month CBZ 2
C 5/month VPA-CZP 3
C 3 /month VPA-CZP 3
12/month CBZ-PB 3
4/month — 4
SG 15/day CBZ-CLB 3
4/day VPA-CLB 3
G = generalized; FSG = focal with secondary generalization;
myoclonic; SP: spasm; Sympt. = symptomatic; Crypt. = crypto-
e CBZ = carbamazepine; CLB = clobazam; CZP = clonazepam;
enytoin; VGB = vigabatrin; VPA = valproate.
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tion range related to efficacy and tolerability.27
In the clinical experience here reported we eval-
uated prospectively a sample of epileptic patients
who started treatment with TPM, in monotherapy or
in add-on. The aim was to investigate the relation-
ship between TPM SL and clinical course, other than
the influence on dosage, age and comedication.Patients and methods
Twenty-seven patients (16males and 11 females; age
range: 16 months—46 years, mean: 22 years) from
EpilepsyCenter of ‘‘E.Medea’’ Institutewere treated
with TPM. In one case TPMwas used asmono-therapy.
In another patient (number 11) TPM was initially
added to CBZ and then, during follow-up, CBZ was
gradually withdrawn. In this patient two TPM SLwere
obtained, before (i.e. bi-therapy with TPM and CBZ)
and after CBZ withdrawal (TPM mono-therapy).
Therefore in seven patients TPMwas used in addition
to another AED. In 19 patients TPM was associated
with two or three AEDs. Clinical data of the patients
are shown in Table 1.
Four patients were also receiving not antiepilep-
tic drugs (hormonal replacement, anti- inflamma-
tories, antiarrhythmic, psycho-tropic, antispastic
drugs). Nineteen patients had focal symptomatic
epilepsy, two focal cryptogenic epilepsy, five symp-
tomatic generalized epilepsy, including two with
progressive myoclonus epilepsy (Unverricht-Lund-
borg disease) and one in whom epilepsy was unde-
termined whether focal or generalized.
Nineteen patients had second grade refractory
epilepsy according to classification proposed by Per-
ucca,17 with persistence of seizures despite at least
two adequate AEDs, used alone or in combination;
furthermore, three patients had third grade refrac-
tory epilepsy. The study was approved by the Institu-
tional Review Board and a written informed consent
was obtained from the patients or their parents.
The initial dose of TPM was 0.5—1 mg/kg/day in
the children (age <15 years) and 25 mg/day in the
adults for 7—10 days. Dosage was then slowly
titrated with 1—3 mg/kg/day or 25 mg/day at 7—
10 days increments until efficacy or side effects
occurred. Target dosage was 5 mg/kg/day in chil-
dren and 100 mg/day in adults. Successively TPM
dosages were eventually increased, if tolerated,
with similar titration schedule, to a maximum
dosage of 10 mg/kg/day in children and 600 mg/
day in adults. The titration was stopped in all cases
where further seizure reduction did not occur.
We included patients whose clinical history and
seizure frequency were well known and were fol-lowed in our Epilepsy Center from at least one year.
Patients were clinically evaluated at the initial visit
before administration of TPM. After 4—5 weeks
when target dose was achieved, they were revalu-
ated through medical examination, clinical labora-
tory tests and monitoring levels of AEDs (including
TPM SL). Subsequently, these evaluations were
repeated after 3 and 6 months, in the first year of
TPM therapy.
A diary of seizure activity was kept by patients
or their parents and examined at each visit. The
average follow-up was 11 months (range: 2—36
months). Responders were considered those
patients who achieved a 50% reduction in mean
seizure frequency at follow-up visits compared
with the baseline period. The quantitative deter-
mination of TPM in serum was measured by the
IMMUNOFLUOR* TOPIRAMATE Assay System, a fluor-
escence polarization immunoassay (FPIA) with an
Abbott TDX instrument. Each assay required at
least 75 ml of serum or heparinized plasma; sam-
ples were collected in the morning before meal
and drug assumption. Hemolyzed samples were
not considered. Patient samples were stored at
2—8 8C for no longer than 24 h or directly frozen
at 20 8C before carrying out biochemical analy-
sis. TPM SL were recorded on the analyzer printout
in mmol/l.
Statistical analysis was performed using t-test for
two groups and analysis of variance (ANOVA) for
more than two. Factors considered were clinical
response, age and comedication with inducing and
not inducing AEDs. All variables were related to both
SL mean and the level to dose ratio (LDR). LDR is the
ratio between TPM SL (mmol/l) and TPM dose per
body weight (mg/kg), as defined by May.6
The relationship with inducing and not inducing
AEDs was first analyzed in all patients, then only in
adults to avoid age as confounding factor. Further-
more, multiple regression analysis was performed
using TPM SL and LDR as dependent variables and
age, TPM dosage and inducing comedication as
independent variables.Results
We analyzed the TPM SL in 43 samples from 27
patients (11 patients had two or more samples).
Eighteen patients received TPM associated with
enzyme-inducing AEDs, eight with not enzyme-indu-
cing AEDs. Five out of 18 cases with enzyme-indu-
cing AEDs also received VPA. The mean steady state
TPM dose was 3.9 mg/kg daily (range 0.7—10.9); the
mean TPM SL was 13.43 mmol/l (range 1.47—34.27).
Mean LDR value was 3.63 mmol/l/mg/kg.
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Figure 1 Relationship between daily TPM dosage and
TPM SL in patients on TPM monotherapy and in those
comedicated with enzyme inducing and not inducing
AEDs. There is a good dosage to SL correspondence due
to TMP linear kinetics. Figure 3 TPM LDR in adult patients treated with indu-
cing and not inducing cotherapy. The treatment with an
inducing comedication turned out to be a factor able to
reduce significantly LDR by multiple regression analysis
and by t-test.
Table 2 Multiple regression analysis with mean TPM
SL as dependent variableFig. 1 shows the relationship between the TPM
daily dosage and the corresponding SL in patients on
TPM monotherapy and in those comedicated with
enzyme-inducing (CBZ, PB, PHT) and not enzyme-
inducing AEDs. Although there is a good dosage to SL
correspondence; there are still some important
deviations depending on age and comedications.
The two children younger than 2 years received
dosages higher than the mean (9 and 4.3mg/kg/day,
respectively) but had SL near (13.67 mmol/l) or
lower (4.2 mmol/l) than the mean with a very low
LDR (0.97 and 1.5 mmol/l/mg/kg, respectively).
Furthermore, all children (age<15 years) had lower
SL (mean 8 mmol/l) than the adults (mean
13.7 mmol/l); this trend, however, was not signifi-
cant (t = 1.65; p = 0.11) (Fig. 2).
The comedication with an enzyme-inducing AED
was another factor able to reduce TPM SL and LDR.
However, only the LDR reduction was significant (t-
test = 2.81; p = 0.010) (Fig. 3).
The mean LDR, calculated separately, was
5.3 mmol/l/mg/kg for patients with not inducing
AEDs and 2.9 mmol/l/mg/kg for those with indu-
cing-enzyme AEDs (2.5 when VPA was also asso-Figure 2 TPM SL in adults versus children (age <15
years). All children had lower SL (mean 8 mmol/l) than
the adults (mean 13.7 mmol/l); this trend, however, was
not significant (t = 1.65; p = 0.11).ciated). These differences, already significant by
ANOVA (F = 3.9; p = 0.035), were much more signif-
icant (F = 11.1; p = 0.008) if only adults were con-
sidered (3.1 mmol/l/mg/kg with inducing AEDs, 2.5
with also VPA, and 7.3 with not inducing).
The treatment with an inducing comedication, by
multiple regression analysis, turnedout to be a factor
able to reduce significantly LDR but not TPM SL. This
result was obtained considering either adults only
(Tables 2 and 3) or whole sample (in this case the
adjusted R2 was 0.45 for SL and 0.32 for LDR). Only
two patients had SL on TPM monotherapy, so a sta-
tistical analysis was not performed on this group.
Efficacy
Four patients became seizure-free. All 4 cases
received TPM dosages lower than the mean. ElevenVariable B S.E. B p
Age (years) 0.237 0.141 0.112
TPM dose (mg/kg) 2.205 0.385 0.000
Inducing/not inducing 5.487 2.934 0.079
Adjusted R2 = 0.66; n = 20 (adult patients); B = regression
coefficient; S.E. B = standard error of B.
Table 3 Multiple regression analysis with LDR as
dependent variable
Variable B S.E. B p
Age (years) 0.046 0.042 0.291
TPM dose (mg/kg) 0.216 0.116 0.082
Inducing/not inducing 4.169 0.888 0.0002
Adjusted R2 = 0.60; n = 20 (adult patients); B = regression
coefficient; S.E. B = standard error of B.
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patients, even if not definable as responders
because their seizure frequency did not decrease,
showed a favorable effect: in fact they had no more
drop-attacks. Their SL mean resulted significantly
higher (23.7 mmol/l) than SL mean in seizure-free
group (9.1 mmol/l) and inefficacy group (8.7 mmol/
l) by ANOVA (F = 4.52; p = 0.015). The patients with
at least 50% seizure reduction had SL mean
(12.8 mmol/l) middle between seizure-free group/
inefficacy group and the group with seizure intensity
reduced, but this trend was not significant.
In four patients efficacy could not be evaluated
because of unsuccessful attempt to reduce asso-
ciated AED in two cases (cases number 11—17),
and because of a short follow-up time in other
two (cases number 20—21).
Adverse effects
None had seizure worsening. In one case TPM was
tapered off because of inefficacy, TPM SL was
13.67 mmol/l (VPA associated). In other three
patients TPM tapering was due to both adverse
effects (sedation, drooling) and inefficacy (none
with SL over the mean; more than two AEDs asso-
ciated).
Repeated samples
Multiple samples were obtained from 11 patients
and in 6 of them overlapping SL and LDR values were
detected without changing therapy.
On the other hand, in the five remaining patients
the LDR was unchanged in all cases except one, both
before and after TPM and/or inducing AED dosages
variations. That particular patient stopped CBZ and
remained on TPM monotherapy, with LDR increas-
ing. All these patients continued to have at least 50%
seizure reduction.Discussion
Our report, although is not a controlled trial, could
be considered a first step to verify clinical utility of
SLTPM monitoring in patients with different clinical
characteristics, namely the type of epilepsy, the
severity of seizure disorder and the type of conco-
mitant medication.
The role and clinical impact of SL monitoring in
AEDs management have been discussed for a long
time. In particular, about new AEDs, on the one hand
several authors affirm scanty utility of SL monitor-
ing,18—21 on the other hand some studies show thatalso these drugs are characterized by several inter-
actions.6,22,23
Although therapeutic SL range of TPM has not
been established yet to allow a routine monitoring,
TPM SL may be useful in selected patients, such as
those suspected of poor compliance and those in
whom pharmacokinetic changes due to disease or
comedication are expected.24,25
The wide interindividual variability in the serum
concentrations at which therapeutic and toxic
effects of these drugs are observed, does not neces-
sarily imply that SL cannot be useful. Indeed, a
marked pharmacodynamic variability has also been
reported for all the older currently monitored antic-
onvulsants.24
Even in the presence of marked interindividual
pharmacodynamic variability, it is often possible to
empirically determine the concentration at which
each patient exhibits the best response, and apply
that information in subsequent management.24
We have considered total TPM SL and not free
fraction because TPM reportedly binds in saturable
manner to erythocytes but minimally to plasma
proteins — around 15% of TPM is bound to plasma
proteins35—37 — so displacement effect, i.e. displa-
cement of VPA binding sites, should not be relevant.
Our SL values are similar to those reported in the
literature26 by using the same methods with respect
to patient’s age and TPM dosages.
The analysis of our sample, even if small and
heterogeneous, confirms a good relationship
between TPM dosages and SL (by multiple regression
analysis, an increase of 1 mg/kg induces an increase
of 2.2 mmol/l, when adults were considered).
Nevertheless it also suggests some considera-
tions. Childhood, because of increased drug clear-
ance, and comedication with enzyme-inducers AEDs
are important factors that reduce TPM SL and LDR,
even if in our analysis a significant LDR reduction
was observed only in presence of enzyme-inducers,
probably due to small sample size. According to the
literature,2—6,33,38 the most relevant TPM SL varia-
tions are expected in case of TPM associated with
inducing-AEDs (CBZ, PHT, PB). On the other hand,
effect of coadministration of VPA is not univocally
predictable in our study, depending upon the asso-
ciation with inducing-AEDs.
Regarding non-antiepileptic comedication, we
have not found data in the literature about drugs
administered to our four patients (namely thyrox-
ine, risperidone, insulin, chloroquine, sotalol, dan-
trolene); only one study38 reports data on the effect
of TPM on risperidone and not vice versa.
About clinical impact of TPM SL, no direct rela-
tionship between SL and efficacy has been demon-
strated in our experience, except that between
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the patients who received TPM dosages higher than
the target dose, with higher SL, achieved full sei-
zure control.
However, also our data seem to indicate low-
medium levels as optimal ones, in accordance with
the recent reported trial.27 Our patients have not
achieved TPM levels so high as 56 mmol/L27 and this
may explain the lower incidence of adverse events
in our experience. Those of our patients who com-
plained adverse effects showed SL below the mean
value. Consistent with our results are the data
reported by another study,31 in which the authors
show that, in patients treated with TPM plus AED
inducers and not inducers, no consistent relation
was observed between TPM plasma concentrations
and adverse effects, mostly involving central ner-
vous system, complained by 34% of patients.
All our patients with adverse effects were on
polytherapy with other two or three AEDs. In parti-
cular, two of these patients were co-treated with
VPA, therefore sedation reported in these cases could
be a symptom of encephalopathy due to combination
of TPM and VPA, as reported by Hamer et al.32 How-
ever, unlike Hamer’s report, in our cases ammonia
concentrations were not elevated. Nevertheless, we
cannot exclude a pharmacodynamic mechanism due
to a direct toxicity of TPM in at risk patiens.34
In conclusion, there seems not to be a direct
relation between high TPM SL and seizure control
neither between high TPM SL and adverse effects.
However, there could be a greater probability to
reduce seizure severity (in particular, to stop drop-
attacks) with high dosages and SL.Acknowledgements
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